Vyant Bio, Inc.
VYNT
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -63.38% | -64.50% | -41.99% | -6.93% | -4.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -63.38% | -64.50% | -41.99% | -6.93% | -4.24% |
| Cost of Revenue | -54.82% | -56.91% | -45.43% | -11.96% | 6.75% |
| Gross Profit | 37.80% | 38.86% | 51.07% | 21.39% | -38.32% |
| SG&A Expenses | -8.79% | -0.48% | 4.44% | 39.77% | 71.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.80% | 2.94% | 13.99% | 44.46% | 62.12% |
| Operating Income | 12.50% | -8.53% | -18.78% | -49.50% | -70.30% |
| Income Before Tax | 18.54% | -0.68% | 14.90% | 3.38% | 3.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.54% | -0.68% | 14.90% | 3.38% | 3.97% |
| Earnings from Discontinued Operations | 97.18% | 91.57% | 69.11% | -1,785.77% | -11,683.75% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.77% | 57.79% | 44.47% | -135.62% | -162.04% |
| EBIT | 12.50% | -8.53% | -18.78% | -49.50% | -70.30% |
| EBITDA | 11.77% | -9.35% | -19.80% | -52.33% | -73.98% |
| EPS Basic | 70.02% | 59.01% | 77.65% | 58.08% | 66.81% |
| Normalized Basic EPS | 18.07% | -2.66% | 56.41% | 71.73% | 79.29% |
| EPS Diluted | 70.02% | 59.01% | 77.65% | 58.08% | 66.81% |
| Normalized Diluted EPS | 18.07% | -2.66% | 56.41% | 71.73% | 79.29% |
| Average Basic Shares Outstanding | 4.63% | 3.09% | 30.15% | 83.53% | 213.11% |
| Average Diluted Shares Outstanding | 4.63% | 3.09% | 30.15% | 83.53% | 213.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |